The American Kratom Association Is Calling 7-OH a "Synthetic Opioid." It Isn't. And They Know It.
NEWS ANALYSIS | July 4, 2026 | Kratom Truth Project
By Kratom Truth Project
When the DEA filed its notice of intent to schedule 7-hydroxymitragynine on July 1, 2026, the American Kratom Association did something remarkable: it cheered.
"Do not ban kratom because of 7-OH," AKA's press release read. "Ban 7-OH because it is not kratom."
The statement positions AKA alongside the DEA, alongside HHS Secretary Kennedy, alongside the same regulatory apparatus that has spent years trying to remove kratom from the market entirely. It also repeats, without challenge, the claim that 7-OH is a dangerous synthetic opioid.
That claim is false. AKA knows it is false. And the decision to repeat it anyway tells you everything you need to know about what AKA is actually protecting.
7-Hydroxymitragynine Is Not a Synthetic Opioid
Let's be precise, because precision matters in a federal regulatory record.
7-hydroxymitragynine is a naturally occurring alkaloid in the Mitragyna speciosa plant. It is present in every batch of whole-leaf kratom that AKA's member vendors sell. It forms naturally through the plant's biosynthetic processes. No laboratory creates it. No chemist synthesizes it. It grows.
The word "synthetic" in chemistry means manufactured through chemical synthesis rather than derived from a natural source. 7-OH is not synthetic. Calling it synthetic is not a matter of interpretation or regulatory framing — it is factually incorrect.
The word "opioid" means a substance that binds to opioid receptors. By that definition, your body produces opioids right now. Beta-endorphin — the compound responsible for the runner's high — is a partial agonist at mu-opioid receptors, the same receptor mechanism as 7-OH. Nobody is scheduling beta-endorphin.
When AKA calls 7-OH a "synthetic opioid" they are using language that belongs to DEA press releases and pharmaceutical industry talking points. They are not describing chemistry. They are choosing a political frame — and the frame they chose is the one their opponents built for them.
The Strategy AKA Is Running — and Why It Will Fail
AKA's position is not scientifically confused. It is strategically calculated. The calculation goes like this:
7-OH products — shots, gummies, concentrated extracts — have generated negative media coverage. "Gas station heroin" headlines. Poison control calls. Regulatory pressure. AKA's member vendors, who primarily sell whole-leaf kratom powder and capsules, compete with these products for market share and lose the PR battle every time one generates a headline.
The calculation: sacrifice 7-OH. Draw a line between "good kratom" (whole-leaf, which AKA represents) and "bad kratom" (concentrated 7-OH, which competes with their members). Let the DEA do the work of clearing the competitive landscape. Call it a public health victory.
This strategy is wrong for three reasons.
It is scientifically wrong because the line AKA is drawing does not exist in chemistry. 7-OH is not a different substance from kratom — it is a component of kratom. Every serving of AKA-certified whole-leaf powder contains 7-OH. The distinction between "botanical kratom" and "7-OH" is a market positioning argument dressed up as science. The DEA's written rule — which contains no natural product exemption — reflects this reality even if AKA's press release does not.
It is strategically self-defeating because it accepts the regulatory premise that concentration equals danger. The FDA will use that premise again. Once AKA concedes that a more concentrated form of a kratom alkaloid is schedulable, they have handed regulators the framework they need to schedule progressively less concentrated forms until whole-leaf kratom is the target. This is not speculation — it is the documented history of cannabis prohibition, where each concession became the foundation for the next restriction.
It is morally indefensible because the people who depend on concentrated 7-OH products are not reckless gas-station customers. Peer-reviewed survey data from Johns Hopkins Medicine found that 91% of kratom users report taking it to alleviate pain and 41% specifically to manage opioid withdrawal. The patients who have moved from whole-leaf kratom to concentrated extracts did so because whole-leaf was not sufficient for their pain levels or withdrawal severity. AKA is making a political calculation that writes those patients out of the community they claim to represent.
Who AKA Is Actually Protecting
The American Kratom Association is a trade association. Its members are primarily whole-leaf kratom vendors. Its funding comes from those vendors. Its political interests align with those vendors.
This is not a criticism — trade associations exist to represent their members' interests. But it is important context when evaluating AKA's position on 7-OH scheduling.
AKA's member vendors compete with concentrated 7-OH products. Those products have taken significant market share. They generate headlines that damage the entire kratom industry's reputation. Clearing them from the market through federal scheduling is commercially advantageous for whole-leaf vendors.
AKA's press release frames their position as protecting kratom consumers. What it actually does is protect whole-leaf kratom vendors from concentrated 7-OH competition — at the expense of the most medically vulnerable people in the kratom community.
The patients who depend on 7-OH extracts for chronic pain or opioid recovery are not AKA's constituents. They are not whole-leaf powder customers. They are concentrated product users, and concentrated product users are exactly what AKA is helping the DEA remove from the market.
The "Synthetic Opioid" Language Is a Betrayal of the Broader Advocacy Project
For years the kratom advocacy community has fought the narrative that kratom is a dangerous opioid. That fight has depended on a consistent argument: kratom is a natural plant with a distinct pharmacological profile that does not behave like pharmaceutical opioids or street drugs. The evidence for this argument is strong. The research supports it. KTP has documented it extensively.
AKA's decision to apply "synthetic opioid" language to a naturally occurring kratom alkaloid undermines that entire argument. If a major kratom advocacy organization is willing to call 7-OH a synthetic opioid for strategic convenience, they have handed regulators and opponents a template for applying the same language to mitragynine — the primary alkaloid in whole-leaf kratom — when it is politically useful to do so.
The framework AKA accepted on July 1 — that opioid receptor activity plus concentration equals dangerous synthetic opioid — is a framework that can be turned against any kratom alkaloid at any concentration. AKA built the weapon and handed it to the people who want to use it against them.
The 7-OH fight is moving fast and the mainstream press is getting it wrong. Subscribe to KTP updates →
What the Comment Record Should Reflect
The public comment period on HHS docket HHS-OASH-2026-0232 closes July 31, 2026. The administrative record that the Attorney General must consider will include whatever the public submits.
AKA's position will be in that record. So will 7-HOPE Alliance's opposition. So will the personal testimonies of every patient who submits a comment through tools like the one KTP built at kratomtruthproject.org/comment-on-7-oh.
What the record should also reflect — clearly and on the basis of documented evidence — is that the organization speaking for "the kratom industry" in support of this scheduling action represents whole-leaf vendors whose commercial interests are served by removing concentrated 7-OH from the market. That conflict of interest belongs in the administrative record alongside AKA's press releases.
The comment period is open. The docket is live. The deadline is July 31.
If 7-OH has kept you off pharmaceutical opioids, off fentanyl, off a dependency cycle that the healthcare system created and then abandoned you to manage alone — your voice in that record is more important than AKA's.
Submit your public comment at:kratomtruthproject.org/comment-on-7-oh
Docket: HHS-OASH-2026-0232 · Deadline: July 31, 2026
Submit Your Public Comment Before July 31
HHS Docket HHS-OASH-2026-0232 is open. KTP built a free generator that writes your personalized comment in under 2 minutes — no form letter, no account required.
Related KTP Coverage:
DEA Files Notice of Intent to Schedule 7-Hydroxymitragynine: What It Actually Means
If 7-OH Is "Synthetic," Where's the Patent? The Contradiction at the Heart of the Ban
Following the Money: Financial Forces Behind Kratom Prohibition
The Kratom Truth Project is an independent investigative journalism platform with no corporate funding or pharmaceutical industry affiliations. All claims are sourced from publicly available government documents, peer-reviewed research, and regulatory filings.
Medical disclaimer: This content is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making decisions about your health or treatment.
Share This Investigation
